Ziyad Al-Aly, a physician-scientist from Washington University in St. Louis, co-authored a paper exploring the groundbreaking effects of GLP-1 drugs. The conversation highlights how these drugs extend beyond diabetes treatment, potentially aiding in reducing risks for substance abuse, neurocognitive disorders, and even conditions like Alzheimer's. Al-Aly discusses the implications of these findings on our understanding of free will and behavior. He also calls for more research to fully unlock the transformative potential of GLP-1 medications.

Dr. Ziyad Al-Aly, a leading expert on Long COVID, and Hazie Thompson, an advocate for marginalized communities affected by the pandemic, address the significant impacts of Long COVID. They discuss the common misperceptions surrounding the condition, emphasizing that over 400 million people may be affected. Dr. Al-Aly shares insights from ongoing research and the importance of patient narratives to inform better healthcare responses. Hazie highlights personal challenges and advocates for systemic changes in treatment and public health awareness.